Document is current

Article History

Accepted: 6 October 2021

First Online: 26 October 2021

Declarations

:

: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

: Emanuel Raschi has received personal fees from Novartis, outside the submitted work. Andrea Ardizzoni has received grants and personal fees from BMS, personal fees from MSD, Eli Lilly, Boehringer, and Pfizer, and grants from Celgene, outside the submitted work. Claudio Zamagni has received grants from Novartis, Roche, Eisai, AstraZeneca, Pfizer, PharmaMar, Tesaro, Pierre Fabre, Ist. Gentili, Teva, Seagen, Eli Lilly, Celgene, MSD, GSK, Amgen, and Daiichi; has received support for attending meetings and/or travel from Novartis, Roche, Pfizer, PharmaMar, Tesaro, Pierre Fabre, Ist. Gentili, and Celgene; and has participated in data safety monitoring or advisory boards for Novartis, Roche, Eisai, AstraZeneca, Pfizer, PharmaMar, Amgen, Tesaro, Quintiles IMS, Eli Lilly, Celgene, MSD, GSK, and Daiichi. Michele Fusaroli, Michelangelo La Placa, Elisabetta Poluzzi, and Fabrizio De Ponti have no conflicts of interest that are directly relevant to the content of this article.

: The datasets analysed during the current study are available in the public domain: .

: Codes are available upon reasonable request to the authors

: ER conceived the study. ER and MF contributed to design of the study. MF contributed to the acquisition and analysis of data. ER drafted the manuscript. All authors contributed to the interpretation of data, critically revised the manuscript and provided final approval.

: This article does not contain any studies with human participants performed by any of the authors. This study is based on anonymous data that can be downloaded from a publicly available source. Therefore, no ethical approval is required.

: Not applicable.

: Not applicable.

Free to read: This content has been made available to all.